Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOMERUS home self-administration of subcutaneous trastuzumab in HER2-positive early breast cancer
NL-OMON47299Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Roche. Primary endpoint: Overall safety and tolerability. Started Feb 2014; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47299.